Lola A. Fashoyin‐Aje

Author

United States Food and Drug Administration ORCID

Also Known As

Abasi Ene-Obong, Bruinooge, Suanna Steeby, L. Fashoyin-Aje, Lola A Fashoyin-Aje, Lola A Fashoyin‐Aje, Lola A. Fashoyin-Aje, Lola A. Fashoyin‐Aje, Lola Fashoyin-Aje, Merrill, Janette, ‘Lola Fashoyin-Aje

124

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Center for Drug Evaluation and Research Johnson & Johnson (United States)Janssen (United States)National Cancer Institute

About

Lola A. Fashoyin‐Aje is an author at United States Food and Drug Administration specializing in medicine, clinical trials, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	520
2	Health Sciences	5	5	228
3	Education	1	1	228
4	Law	1	1	40
5	Nursing	1	1	20

Lola A. Fashoyin‐Aje

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue, Clinical Cancer Research	2021	532
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement Randall A. Oyer, Patricia A. Hurley, Leigh Boehmer, Journal of Clinical Oncology EthnicityConcerted CommitmentHealth Care DisparityCancer ManagementAmerican Society	2022	228
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 Lola A. Fashoyin‐Aje, Martha Donoghue, Huanyu Chen, The Oncologist	2018	224
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma Sandra J. Casak, Martha Donoghue, Lola A. Fashoyin‐Aje, Clinical Cancer Research	2020	170
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma Sandra J. Casak, Leigh Marcus, Lola A. Fashoyin‐Aje, Clinical Cancer Research	2021	167
FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration. Harpreet Singh, Bindu Kanapuru, Che Smith, Journal of Clinical Oncology Geriatric PsychiatryCancer ManagementEpidemiology Of CancerCancer RegistrationEpidemiology Of Aging	2017	154
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer Suparna Wedam, Lola A. Fashoyin‐Aje, Erik Bloomquist, Clinical Cancer Research	2019	149
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Clinical Cancer Research	2020	142
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials Jeanne M. Regnante, Nicole Richie, Lola A. Fashoyin‐Aje, Journal of Oncology Practice	2019	93
FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer Suparna Wedam, Lola A. Fashoyin‐Aje, Xin Gao, Clinical Cancer Research	2020	84

Page 1